Tiziana Life Sciences (TLSA) announced that its grant application to the ALS Association has been approved for funding. The grant is awarded as part of the Hoffman ALS Clinical Trial Awards Program and is titled “Modulation of ALS neuroinflammation by nasal anti-CD3 monoclonal Antibody”. The Association’s grant will fund a 20-patient clinical trial of two doses of Tiziana’s novel and patented therapeutic candidate, intranasal foralumab, aimed at evaluating the safety and early-stage parameters of disease improvement in Amyotrophic Lateral Sclerosis, ALS, also known as Lou Gehrig’s disease.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TLSA:
- Tiziana Life Sciences Highlights Advancements at BIO-Europe 2024
- Tiziana Life Sciences Announces $10 Million Share Offering
- Tiziana Life Sciences Reports Promising Obesity Therapy Results
- Tiziana Life Sciences announces results from ozempic, nasal anti-CD3 study
- Tiziana Life Sciences Plans Share Sale with Jefferies